SCHEMBL4859938

SCHEMBL4859938

c1ccc(CNc2nc(Cc3ccccc3)nc3ccccc23)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.69
KMT2A Q03164 3/20 0.67
LMNA P02545 2/20 0.67
KDM4E B2RXH2 1/20 0.67
ALDH1A1 P00352 1/20 0.67
MAPT P10636 1/20 0.67
PKM P14618 1/20 0.67
UBE2N P61088 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
RCE1 Q9Y256 1/20 0.67
ACHE P22303 5/20 0.66
BCHE P06276 4/20 0.66
APP P05067 5/20 0.65
PDE5A O76074 4/20 0.65
PDE4A P27815 2/20 0.63
PDE4B Q07343 2/20 0.63
PDE4C Q08493 2/20 0.63
PDE4D Q08499 2/20 0.63
PDE3B Q13370 1/20 0.63
PDE3A Q14432 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864671 0.88 APP (0.70) RAD52KMT2ALMNAKDM4EALDH1A1
SCHEMBL4861406 0.86 APP (0.71) RAD52KMT2ALMNAKDM4EALDH1A1
SCHEMBL3976866 0.86 APP (0.68) RAD52KMT2ALMNAKDM4EALDH1A1
SCHEMBL4894183 0.86 RAD52 (0.51) RAD52KMT2ALMNAKDM4EALDH1A1
SCHEMBL4864862 0.84 APP (0.68) KMT2ALMNAKDM4EACHEBCHE
SCHEMBL4866192 0.84 APP (0.61) RAD52KMT2ALMNAKDM4EALDH1A1
SCHEMBL4866244 0.83 MAPK1 (0.59) RAD52KMT2ALMNAKDM4EALDH1A1
SCHEMBL4866870 0.83 APP (0.73) RAD52KMT2AACHEBCHEAPP
SCHEMBL4866326 0.83 APP (0.73) KMT2ALMNAALDH1A1MAPTACHE
SCHEMBL4867646 0.82 ACHE (0.58) KMT2ALMNAALDH1A1ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R RAD52 3911/4885KMT2A 1662/4885LMNA 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.